X0508 4 2026-02-02 0 0001737287 Allogene Therapeutics, Inc. ALLO 0001296549 Belldegrun Arie 210 EAST GRAND AVE SOUTH SAN FRANCISCO CA 94080 1 0 0 0 0 Common Stock 4710120 I See footnote Common Stock 1798163 I See footnote Common Stock 1724137 I See footnote Common Stock 539867 I See footnote Common Stock 2236816 D Stock Option (Right to buy) 1.87 2026-02-02 4 A 0 929913 0 A 2036-02-02 Common Stock 929913 929913 D Restricted Stock Unit 2026-02-02 4 A 0 263033 0 A Common Stock 263033 263033 D The securities are held in the name of Bellco Legacy Trust fbo Rebecka Belldegrun, of which the reporting person's spouse is trustee and beneficiary The securities are held by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager. There porting person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The securities are held by Vida Ventures III, L.P. and Vida Ventures III-A, L.P. Vida Ventures GP III, LLC is the manager of Vida Ventures III, L.P. and Vida Ventures III-A, L.P. The reporting person is a Senior Managing Director of Vida Ventures GP III, LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida Ventures III, L.P. and Vida Ventures III-A, L.P. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The securities are held in the name of Bellco Legacy LLC. Bellco Legacy LLC is owned and managed by trusts controlled by the reporting person and Rebecka Belldegrun. 25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter. Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period from February 2, 2026, subject to continued service through the vesting date. /s/Earl Douglas, Attorney-in-Fact 2026-02-04